MeSH term
Frequency | Condition_Probility | *Chromosome Aberrations | 2 | 0.0 |
Humans | 15 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Research Support, Non-U.S. Gov't | 9 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Base Sequence | 2 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Cell Line | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Comparative Study | 3 | 0.0 |
Molecular Sequence Data | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 4 | 0.0 |
Female | 6 | 0.0 |
*Gene Amplification | 4 | 1.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Male | 4 | 0.0 |
Trans-Activators/*genetics | 2 | 0.0 |
*Chromosomes, Human, Pair 20 | 3 | 2.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Amino Acid Sequence | 2 | 0.0 |
Aged | 2 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Middle Aged | 2 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Gene Amplification/genetics | 2 | 3.0 |
Gene Dosage | 2 | 0.0 |
